2023 World Conference on Lung Cancer (Posters)-EP12.01. Good Results of Osimertinib in a Patient with EGFR (L861Q) and MET Amplification NSCLC: A Case Report

EP12.01. Good Results of Osimertinib in a Patient with EGFR (L861Q) and MET Amplification NSCLC: A Case Report - PDF(Slides)

Back to course

Pdf Summary

A case report describes a 62-year-old man with a pleomorphic poorly differentiated infiltrating adenocarcinoma in the upper lobe of the right lung. The tumor had metastasized to the esophagus and bone, and the patient presented with neck and lumbar pain. The tumor had EGFR(L861Q) mutation, which is known for its resistance to EGFR-TKIs. The patient was treated with osimertinib 80 mg/24 hs and denosumab 120 mg every 4 weeks, along with 15 sessions of radiotherapy to the cervical spine. The patient achieved partial response twice with a progression-free survival rate of 8.13 months.<br /><br />However, unexpected metastatic subcortical lesions in the parietal and frontal lobes were found, as well as a narrowing of the cervical canal. These new lesions had developed a resistance mutation called MET amplification. Although a next-generation sequencing study of cerebrospinal fluid revealed this resistance mutation, the patient could not receive Amivantamab, the recommended treatment, because it was not commercially available at the time.<br /><br />Palliative measures were continued until the patient's unfortunate death. The case report highlights the challenges faced in treating a patient with an uncommon EGFR mutation and resistance mechanisms. Despite the partial response achieved with osimertinib, the emergence of MET amplification and the lack of access to appropriate treatment options led to an unfavorable outcome.<br /><br />Table 1 provides a summary of the patient's imaging follow-up, showing the progression of the disease in various sites. The report emphasizes the need for further research and access to innovative treatments to improve outcomes for patients with resistant mutations in non-small cell lung cancer.

Asset Subtitle

Iván Romarico González-Espinoza

Meta Tag

Speaker Iván Romarico González-Espinoza

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

lung cancer

adenocarcinoma

metastasis

EGFR mutation

EGFR-TKIs resistance

osimertinib

denosumab

radiotherapy

MET amplification

palliative measures